Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?

by Zacks Equity Research

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.

Zacks Equity Research

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

by Zacks Equity Research

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

Zacks Equity Research

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

by Zacks Equity Research

CMRX and JAZZ are in the spotlight this week following an acquisition agreement.

Zacks Equity Research

Here's Why Moderna Stock Soared 16% on Wednesday

by Zacks Equity Research

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Kinjel Shah headshot

Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?

by Kinjel Shah

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Zacks Equity Research

Moderna (MRNA) International Revenue Performance Explored

by Zacks Equity Research

Explore how Moderna's (MRNA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Kinjel Shah headshot

Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus

by Kinjel Shah

Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

by Zacks Equity Research

MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.

Sundeep Ganoria headshot

Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?

by Sundeep Ganoria

Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.

Zacks Equity Research

Stock Market News for Feb 18, 2025

by Zacks Equity Research

Wall Street was closed on Monday for Presidents' Day.